{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:22:51Z","timestamp":1777677771589,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T00:00:00Z","timestamp":1537228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1 ULTR001449"],"award-info":[{"award-number":["1 ULTR001449"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["5U18PS004568-03"],"award-info":[{"award-number":["5U18PS004568-03"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Health Promotion Practice"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Introduction. Young adults who inject drugs and live in rural communities are at high risk for hepatitis C virus (HCV) infection. Recent changes in HCV treatment must be communicated within these communities to improve access to care and reduce HCV transmission. Methods. Field workers in the \u00a1V\u00c1LE! Hepatitis Treatment and Integrated Prevention Services study identified frequently asked questions (FAQs) posed by young-adult participants at high risk for HCV during screening and educational sessions. From 2016 to 2018, 183 young adults (44.3% women; 85.8% Latino\/a) younger than 30 years who inject drugs and reside in Rio Arriba or Do\u00f1a Ana counties in New Mexico were enrolled. The research team compiled deidentified questions during field enrollments. Results. FAQs were reviewed and categorized into four major domains, including risk\/prevention, screening, treatment, and reinfection. FAQs were addressed by a team of medical and public health professionals, using the most current research and recommendations. Conclusions. These FAQs address important gaps in HCV knowledge among young adults who are at high risk for infection. The FAQs also highlight the importance of risk reduction counseling provided by frontline public health providers as well as access to safe and effective HCV treatments for young adults who inject drugs.<\/jats:p>","DOI":"10.1177\/1524839918799455","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T01:35:05Z","timestamp":1537320905000},"page":"815-822","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Talking About Hepatitis C: FAQs From Young Adults Who Inject Drugs"],"prefix":"10.1177","volume":"19","author":[{"given":"Lauren L.","family":"Knight","sequence":"first","affiliation":[{"name":"University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Wagner","sequence":"additional","affiliation":[{"name":"University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuridia","family":"Leyva","sequence":"additional","affiliation":[{"name":"University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica R.","family":"Bruce","sequence":"additional","affiliation":[{"name":"University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten A. M.","family":"White","sequence":"additional","affiliation":[{"name":"University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne S.","family":"Talamantes","sequence":"additional","affiliation":[{"name":"University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Price","sequence":"additional","affiliation":[{"name":"University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Page","sequence":"additional","affiliation":[{"name":"University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2295-5062","authenticated-orcid":false,"given":"Martha L.","family":"Carvour","sequence":"additional","affiliation":[{"name":"University of New Mexico Health Sciences Center, Albuquerque, NM, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,9,18]]},"reference":[{"key":"bibr1-1524839918799455","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. (2018). HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Alexandria, VA: Author. Retrieved from https:\/\/www.hcvguidelines.org\/"},{"key":"bibr2-1524839918799455","doi-asserted-by":"crossref","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America HCV Guidance Panel. (2015). Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus: Hepatitis C virus guidance panel. Hepatology, 62, 932-954. https:\/\/doi.org\/10.1002\/hep.27950","DOI":"10.1002\/hep.27950"},{"key":"bibr3-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv017"},{"key":"bibr4-1524839918799455","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2460"},{"key":"bibr5-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1177\/2049936115585942"},{"key":"bibr6-1524839918799455","unstructured":"Centers for Disease Control and Prevention. (2013). Interpretation of results of tests for hepatitis C virus (HCV) infection and further actions. Atlanta, GA: Author. Retrieved from https:\/\/www.cdc.gov\/hepatitis\/hcv\/pdfs\/hcv_graph.pdf"},{"key":"bibr7-1524839918799455","unstructured":"Centers for Disease Control and Prevention. (2016). Hepatitis C questions and answers for the public. Atlanta, GA: Author. Retrieved from https:\/\/www.cdc.gov\/hepatitis\/hcv\/cfaq.htm"},{"key":"bibr8-1524839918799455","unstructured":"Centers for Disease Control and Prevention. (2017). Surveillance for viral hepatitis-United States, 2015. Atlanta, GA: Author. Retrieved from https:\/\/www.cdc.gov\/hepatitis\/statistics\/2015surveillance\/commentary.htm"},{"key":"bibr9-1524839918799455","unstructured":"Centers for Disease Control and Prevention. (2018). Hepatitis C questions and answers for health professionals. Atlanta, GA: Author. Retrieved from https:\/\/www.cdc.gov\/hepatitis\/hcv\/hcvfaq.htm"},{"key":"bibr10-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir535"},{"key":"bibr11-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27978"},{"key":"bibr12-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.2005.01076.x"},{"key":"bibr13-1524839918799455","doi-asserted-by":"publisher","DOI":"10.2807\/esm.10.05.00535-en"},{"key":"bibr14-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00225.x"},{"key":"bibr15-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000171412.61360.f8"},{"key":"bibr16-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1086\/649783"},{"key":"bibr17-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1086\/345554"},{"key":"bibr18-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000191281.77954.27"},{"key":"bibr19-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1136\/sti.79.2.160"},{"key":"bibr20-1524839918799455","unstructured":"National Viral Hepatitis Roundtable and Center for Health Law and Policy Innovation at Harvard Law School. (2018). Hepatitis C state of Medicaid access. Washington, DC: Author. Retrieved from https:\/\/stateofhepc.org\/"},{"key":"bibr21-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1086\/656212"},{"key":"bibr22-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12117"},{"key":"bibr23-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26744"},{"key":"bibr24-1524839918799455","unstructured":"Steckelberg J. (2017, November 9). Why isn\u2019t there a hepatitis C vaccine? Rochester, MN: Mayo Clinic. Retrieved from https:\/\/www.mayoclinic.org\/diseases-conditions\/hepatitis-c\/expert-answers\/hepatitis-c-vaccine\/faq-20110002"},{"key":"bibr25-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu643"},{"key":"bibr26-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1086\/428128"},{"key":"bibr27-1524839918799455","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2013.301812"},{"key":"bibr28-1524839918799455","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.07.002"},{"key":"bibr29-1524839918799455","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2017.304132"}],"container-title":["Health Promotion Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1524839918799455","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1524839918799455","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1524839918799455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:25:18Z","timestamp":1777451118000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1524839918799455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,18]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1177\/1524839918799455"],"URL":"https:\/\/doi.org\/10.1177\/1524839918799455","relation":{},"ISSN":["1524-8399","1552-6372"],"issn-type":[{"value":"1524-8399","type":"print"},{"value":"1552-6372","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,18]]}}}